5 August 2024
Oxford Nanopore Technologies
plc
Oxford Nanopore to sequence
10,000 genomes for Singapore's National Precision Medicine (NPM)
programme
Oxford Nanopore Technologies plc
(LSE: ONT) ("Oxford Nanopore"), the Company delivering a new
generation of nanopore-based molecular sensing technology, notes
the announcement of a landmark project with Singapore's National
Precision Medicine (NPM) programme, led by Precision Health
Research, Singapore (PRECISE), to sequence 10,000 genomes
representing Singapore's diverse population, including Malay,
Indian and Chinese communities.
The project is aimed at developing a
catalogue of structural variants that have demonstrated
significance in helping clinician scientists and researchers in
understanding human genetic diversity and diseases. The Oxford
Nanopore platform was selected by the NPM programme through a
competitive process because of its scalability and flexibility in
sequencing both short and ultra-long DNA/RNA fragments, including
detection of methylation, without the need for additional steps and
at speeds faster than other platforms.
This initiative underscores Oxford
Nanopore's commitment to advancing genetic research and healthcare
outcomes on a global scale, particularly for ethnically diverse
populations that are typically underrepresented in genomic
databases.
The project started mid-2024 and is
expected to run for c.12 months. There is no change to the
Company's already stated 2024 and medium-term financial
guidance.
Gordon Sanghera, CEO of Oxford Nanopore
commented:
"We are excited to collaborate with
Singapore's National Precision Medicine (NPM) programme to create
one of the most extensive and inclusive reference genome datasets
globally. This collaboration not only enhances our commitment to
precision healthcare but also strategically positions Singapore as
a pivotal hub for genomics in the Asia Pacific, fostering
significant advancements in medical research and healthcare
outcomes."
Read more about the project
here:
https://nanoporetech.com/news/singapore-s-national-precision-medicine-npm-programme-engages-oxford-nanopore-to-advance-understanding-of-the-genetics-of-singapore-s-multi-ethnic-population
[ENDS]
For further information, please
contact:
Oxford Nanopore Technologies plc
Investors:
ir@nanoporetech.com
Media:
media@nanoporetech.com
Teneo (communications adviser to the
Company)
Tom Murray, Olivia Peters
+44 (0) 20 7353 4200
OxfordNanoporeTechnologies@teneo.com
About Oxford Nanopore Technologies plc:
Oxford Nanopore Technologies' goal
is to bring the widest benefits to society through enabling the
analysis of anything, by anyone, anywhere. The company has
developed a new generation of nanopore-based sensing technology
that is currently used for real-time, high-performance, accessible,
and scalable analysis of DNA and RNA. The technology is used
in more than 120 countries, to understand the biology of humans,
plants, animals, bacteria, viruses and environments as well as to
understand diseases such as cancer. Oxford Nanopore's technology
also has the potential to provide broad, high impact, rapid
insights in a number of areas including healthcare, food and
agriculture.
Oxford Nanopore devices sequence DNA
and RNA directly and sequence short to ultra-long fragments of DNA,
for a truly comprehensive picture of the genome. Data is streamed
in real-time and can enable rapid insights. The technology is
fully scalable - from pocket-sized to ultra-high throughput
devices.
For more information please
visit: www.nanoporetech.com
About Precision Health Research, Singapore
(PRECISE):
Precision Health Research, Singapore
(PRECISE) is the central entity set up to coordinate a whole of
Singapore effort to implement Phase II of Singapore's three-phase
National Precision Medicine (NPM) programme.
NPM Phase II aims to transform
healthcare in Singapore and improve patient outcomes through new
insights into the Asian genome and data-driven healthcare
solutions. In NPM Phase II, PRECISE will collaborate with Singapore
research and clinical partners, including the Agency for Science,
Technology and Research (A*STAR), Lee Kong Chian School of
Medicine, National Healthcare Group, National University Health
System, National University of Singapore, and SingHealth
Duke-NUS Academic Medical Centre to study the genetic makeup
of 100,000 healthy Singaporeans and specific patient cohorts. The
genetic data will be integrated with detailed lifestyle,
environmental, and clinical data to yield rich insights into
factors that contribute to Asian diseases and
conditions.
Additionally, NPM Phase II
will enhance the breadth and depth of the Precision
Medicine-related industry by attracting and anchoring overseas
companies in Singapore, while yielding new opportunities for
home-grown companies. To enhance and accelerate the precision
medicine sector, PRECISE works in close collaboration with A*STAR,
the Biomedical Sciences Industry Partnership Office, and the
Economic Development Board to catalyse the next phase of growth for
Singapore's healthcare and the biomedical technology
industries.
PRECISE is a programme of the
Consortium for Clinical Research and Innovation, Singapore (CRIS).
PRECISE is supported by the National Research Foundation, Singapore
(NRF) under the RIE2020 White Space (MOH-000588 and MOH-001264) and
administered by the Singapore Ministry of Health through the
National Medical Research Council (NMRC) Office, MOH Holdings Pte
Ltd
For more information, visit
www.npm.sg
Forward-looking statements
This announcement contains certain
forward-looking statements. For example, statements regarding
expected revenue growth and profit margins are forward-looking
statements. Phrases such as "aim", "plan", "expect", "intend",
"anticipate", "believe", "estimate", "target", and similar
expressions of a future or forward-looking nature should also be
considered forward-looking statements. Forward-looking statements
address our expected future business and financial performance and
financial condition, and by definition address matters that are, to
different degrees, uncertain. Our results could be affected by
macroeconomic conditions, the COVID-19 pandemic, delays in our
receipt of components or our delivery of products to our customers,
suspensions of large projects and/or acceleration of large products
or accelerated adoption of pathogen surveillance. These or other
uncertainties may cause our actual future results to be materially
different than those expressed in our forward-looking
statements.